Loading…
Medical Sensors Design Conference 2018 has ended
Tuesday, June 26 • 9:00am - 9:45am
Keynote: Transforming Care Models and Business Models with Digital Medicines

Sign up or log in to save this to your schedule and see who's attending!

Feedback form is now closed.
November 2017 was a pivotal moment for the emerging field of digital medicine: the U.S. Food and Drug Administration approved the world’s first NDA for a medicine including an ingestible sensor and an associated digital care management offering. ABILIFY MYCITE, developed by Otsuka Pharmaceutical and Proteus Digital Health, represents the first new category of drug approved by FDA since 1982 and is a new way to treat patients living with severe mental illness. The product and the expanding digital medicine field it represents also signals the emergence of a new business model for the pharmaceutical industry, one based on the integration of medications with hardware, software, analytics and services as well as one directly linked to patient-specific outcomes as the measure of pharmaceutical value and pricing. In this Keynote Session, David O'Reilly provides background and insights into the potential for digital medicine and the opportunities and challenges for the pipeline of products now being developed and commercialized in this field.

Speakers
avatar for David O'Reilly

David O'Reilly

Chief Platform Officer, Proteus Digital Health
David O’Reilly is Chief Platform Officer of Proteus Digital Health and leads the company’s sensor technology, operations and manufacturing, corporate development and corporate strategy groups. He was formerly Chief Product Officer of Proteus where he built and led the company's... Read More →


Tuesday June 26, 2018 9:00am - 9:45am
Meeting Room 230B

Attendees (4)